A heart transplant center experience with basiliximab induction strategies: A double edged sword?
Luise HolzhauserMaxwell NorrisMaria MolinaSusan ChambersSwethika SundaravelEman RashedKetan GalaTara FallahTherese BittermannNosheen RezaTeresa S WangPavan AtluriLee R GoldbergRhondalyn McLeanEliot G PeysterPublished in: Clinical transplantation (2024)
Basiliximab reduces the incidence of ACR but increases the risk of AMR, CAV, and may be associated with increased mortality. Mechanistic studies are needed to describe a potential T-cell-escape mechanism with enhanced humoral immunity.